Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 10Prostatic Neoplasms 7Lung Neoplasms 6Recurrence 4Multiple Myeloma 4Lymphoma, B-Cell 4Lymphoma 4Colorectal Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Urologic Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia 2Kidney Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Vasculitis 1Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × CRC × 90 days × Clear all
NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡